Skip to content

Safety and Usability Evaluation of the Fidmi Low-Profile Enteral Feeding Device

Safety and Usability Evaluation of the Fidmi Low-Profile Enteral Feeding Device

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03007511
Acronym
Fidmi
Enrollment
20
Registered
2017-01-02
Start date
2017-05-22
Completion date
2022-12-30
Last updated
2022-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia, Feeding Tube

Keywords

Percutaneous Endoscopic Gastrostomy, Feeding tube, Enteral nutrition, Endoscopy, Gastrointestinal

Brief summary

A First In Human Usability Open Label trial will be performed using the Fidmi Feeding device on 20 adult patients with a need for enteral feeding. The primary outcome will be to evaluate safety, usability and discomfort throughout the study

Detailed description

A gastrostomy is a feeding tube that communicates from the skin directly into the stomach. It is a device frequently used in patients that have feeding difficulties or are unable to maintain normal growth via oral feeds. Currently there are many solutions in the market for long-term enteral feeding, however none of them provide comfort and autonomy to their users, since they have a high probability of dislodgement, clogging, leakage and are bulky. The Fidmi Medical PEG Feeding Tube and Accessories are to provides food, liquids and medications into the stomach of patients who are having difficulty of swallowing. Fidmi Feeding Device is the first presented low-profile device from day 1, easily hidden under clothing and not limiting mobility. Unlike other solutions, Fidmi device is resistant to dislodgement due to a semi-rigid internal bumper, and avoids clogging thanks to a disposable insert to deliver the nutrition. Fidmi device consists of 1) a rigid-core silicone bumper that prevents dislodgment, 2) a disposable internal tube replacement for a daily nutrition supply and prolonged patency, and 3) an external flexible bolster that keeps the stoma site ventilated and stable. The disposable insert is placed inside the feeding port and is replaced every 1-2 weeks to avoid clogging, extend the product life, and improve the cleanliness and hygiene of the tube. Disposable tube replacement is easy and safe and can be done by the patients themselves or their caregivers as the tract is never compromised and there is no need for a physician verification. The device is eventually removed in a simple procedure that can be done by the caregiver or patient themselves. Fidmi device obtain a tool that dismantles the internal bumper into small parts that are naturally expelled from the body for trauma free-removal. The Fidmi Feeding device would be inserted into eligible enrolled patients who would be followed up during a period of 3 months until device removal. Safety, usability and discomfort parameters would be monitored following 2, 30, 60, 90 and 120 days following the insertion procedure. In case a new Fidmi PEG device is requested by a patient: additional duration of 120 days±14 days will be added.

Interventions

DEVICEFidmi enhanced enteral feeding device

Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.

Sponsors

Hadassah Medical Organization
CollaboratorOTHER
Fidmi Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female patient 18 up to 90 years. 2. Consecutive adult patients suffering from dysphagia with need for enteral feeding (PEG). 3. Ability to give informed consent for the study by patient or legal guardian. 4. Willingness to undergo 4 follow up visits 1, 3 and 4 months following PEG insertion/replacement, as well as unscheduled sick visits.

Exclusion criteria

1. Pregnancy (all women of child-bearing age would be questioned and told by the consenting physician regarding that criteria). 2. All current practice PEG contraindication 3. Acute gastrointestinal bleeding 4. Extreme obesity patients (BMI\>40) 5. Emergency endoscopy 6. Infectious disease local or systemic (e.g.- sepsis, pancreatitis) 7. Known esophageal pathology (e.g.- stenosis, eosinophilic esophagitis, varices, achalasia) 8. In case of PEG replacement: lack of a well healed gastrostomy or Infection around the insertion site. 9. Known gastric pathology that may prevent safe device insertion, feeding, removal and Bumper flanges expulsion according to the investigator discretion. 10. Any history of bowel obstruction, pseudo-obstruction. 11. Crohn's disease 12. Recurrent vomiting 13. Inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other contraindication to endoscopy 14. Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.

Design outcomes

Primary

MeasureTime frameDescription
Treatment related Adverse EventsThrough study completion, an average of 4 monthsNumber of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0

Secondary

MeasureTime frameDescription
Ease of the device placement procedure (using the 10-point Visual analogue scale satisfaction)at Day 0Scored by the investigator performing the procedure
Ease of the device removal procedure (using the 10-point Visual analogue scale satisfaction)at 3 MonthsScored by the investigator performing the procedure
Accidental dislodgementsuntil device removal at 3 monthsNumber of accidental dislodgements during study follow up
Patient Painat 3 monthsPatient Pain on the Visual Analog Scale during device removal and sedative medication if administrated

Other

MeasureTime frameDescription
Validate (True/False) correct (color) selection of 'Measuring Cannula' by residual tube measurementat day 0design outcome

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026